123456789011234567890111234567890212234567	 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for KEBLIDI safely and effectively. See full prescribing information for thraputaminal infusion MIGHLIGHTS OF PRESCRIBING INFORMATION KEBLIDI (eladocagene exuparvovec-tneq) suspension, for intraputaminal infusion MIGHLIGHTS OF APPOVAL 2024 MEDI (eladocagene exuparvovec-tneq) suspension, for intraputaminal infusion (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on change from baseline in gross motor milestone achievement at 48 weeks post-treatment. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. (1, 14) ————————————————————————————————————	334 335 337 339 412 444 445 447 490 555 555 555 555 555 555 555 555 555 5	 DOSAGE FORMS AND STRENGTHS
27 28 29 30 31 32 64 65 66		59 60 61 62 63	To report SUSPECTED ADVERSE REACTIONS, contact PTC Therapeutics, Inc at toll-free phone 1-866-562-4620 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2024
67	FULL PRESCRIBING INFORMATION: CONTENTS*	88	
68 69 70 71 72 73 74 75 76 77 78 80 81 82 83 84 85 86 87	 INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION Important Dosing Information Recommended Dose Preparation Recommended Dose Procedural Complexity of the contract of	89 90 91 92 93 94 95 96 97 98 99 100 101 102 103	 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.6 Immunogenicity 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed.

- 6.1 Clinical Trials Experience
 8 USE IN SPECIFIC POPULATIONS
 8.1 Pregnancy
 8.2 Lactation
 8.3 Females and Males of Reproductive Potential
 8.4 Pediatric Use
 8.5 Geriatric Use

105 1 INDICATIONS AND USAGE

106 KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based

- gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino
 acid decarboxylase (AADC) deficiency.
- 109 This indication is approved under accelerated approval based on the change from baseline in
- 110 gross motor milestone achievement at 48 weeks post-treatment [see Clinical Studies (14)].
- 111 Continued approval for this indication may be contingent upon verification and description of
- 112 clinical benefit in a confirmatory clinical trial.

113 2 DOSAGE AND ADMINISTRATION

114 For single-dose intraputaminal infusion only.

115 2.1 Important Dosing Information

- Confirm patient has AADC deficiency due to biallelic mutations in the *DDC* gene.
- Strictly observe aseptic technique during preparation and administration of KEBILIDI.
- KEBILIDI should be administered in a medical center which specializes in stereotactic neurosurgery.
- Administer KEBILIDI only using an FDA-authorized cannula for intraparenchymal infusion (i.e., ClearPoint SmartFlow Neuro Cannula Part Number NGS-NC-01-EE or NGS-NC-02-EE).
- Use of the syringe (i.e., connecting the syringe to the syringe pump and priming of the cannula) should begin within 6 hours of starting product thaw.
- KEBILIDI is intended to be administered with an infusion pump capable of infusing at a rate of 0.003 mL/min.

127 **2.2 Recommended Dose**

128 KEBILIDI is administered as four intraputaminal infusions in a single stereotactic neurosurgical129 procedure as per the recommended dose shown in Table 1.

130 Table 1: Recommended Dose of KEBILIDI

Total Recommended Dose	1.8x10 ¹¹ vg (0.32 mL)	
Total number of infusions	4	
Volume (dose) per infusion	0.08 mL (0.45x10 ¹¹ vg)	
Location of infusions	2 in anterior putamen, 2 in posterior putamen	
Infusion rate at each target point	0.003 mL/min	
Dose duration for infusion at each target point	27 minutes	

131 2.3 Preparation

- 132 <u>Thawing KEBILIDI Vial</u>
- Coordinate timing of KEBILIDI thaw and infusion. KEBILIDI should be used within 6
 hours of starting product thaw. Infusion of KEBILIDI takes 4 hours. The maximum time
 from thaw to completion of infusion should be no more than 10 hours.

- Thaw the KEBILIDI vial upright at room temperature before use. The contents of the vial
 will thaw in approximately 15 minutes at room temperature. Do not thaw or warm the
 vial any other way. Gently invert the vial 3 times. Do not shake the vial.
- Inspect the fully thawed KEBILIDI vial after mixing. KEBILIDI should be inspected visually for particulate matter, and discoloration prior to administration. KEBILIDI is clear to slightly opaque. The color of KEBILIDI should be a colorless to faint white suspension.
- **Do not** use if particulates, or discoloration are visible in the suspension.
- 144 <u>Preparing KEBILIDI in Syringe</u>
- 145 1. Gather supplies listed in Table 2 for preparation:

146 Table 2: Supplies for KEBILIDI Preparation

Component	Material of Construction
1mL lubricated sterile Luer-lock syringe with elastomer plunger Or	Silicone, PC; Silicone, PP
5mL lubricated sterile Luer-lock syringe with elastomer plunger	Silicone, PP
18 or 19 G sterile needle with 5µm filter	Stainless steel, PC hub; Stainless steel, PP hub
Sterile Luer-lock syringe cap	-
Plastic bag for delivery into surgical unit	-
Secondary container for delivery into surgical unit	-


147 Abbreviations: PC=Polycarbonate; PP=Polypropylene

- Prepare KEBILIDI using sterile techniques under aseptic conditions, proper engineering controls (e.g., biological safety cabinets or isolator) as per the institutional policies.
- 150 3. Open the syringe and label it as the product-filled syringe.
- 151 4. Attach the filter needle to the syringe.
- 5. Draw the full volume of the vial of KEBILIDI into the syringe. Invert the vial and
 syringe and partially withdraw or angle the needle as necessary to maximize recovery of
 product.
- braw air into the syringe so that the needle is emptied of product. Carefully remove the
 needle from syringe containing KEBILIDI. Purge the air from the syringe until there is
 no air bubble and then cap with a syringe cap.
- 158 7. Place the syringe in a plastic bag and seal the bag.
- 8. Place the plastic bag in an appropriate secondary container for delivery to the surgical suite at room temperature.
- 9. The filled syringe prepared under aseptic conditions for delivery to the surgical siteshould be used immediately.
- 163 <u>Notes:</u>
- **Do not** refreeze thawed product.
- Dispose any remaining KEBILIDI or disposable material in compliance with institutional policy.

167 2.4 Administration

- 168 <u>Gather supplies for administration:</u>
- 169 KEBILIDI [see How Supplied/Storage and Handling (16)]
- 170 SmartFlow Neuro Cannula
- Syringe pump, capable of an infusion rate of 0.003 mL/min and compatible with 1 mL or
- 1725 mL syringe sizes172Standard structure
- 173 Stereotactic system
- 174 Identification of the Target Points Within the Putamen
- Using standard neurosurgical stereotactic procedure, brain imaging for stereotactic planning and intraoperative navigation should be done prior to the procedure (see Figure 1).


178 Figure 1: Four Target Points within the Putamen for Infusion Sites



179

After stereotactic registration is complete, mark the entry point on the skull. Surgical access through the skull bone and dura should be performed.

182 Figure 2: Infusion Delivery System



183

184 Intraputaminal Administration of KEBILIDI

185 Administer KEBILIDI by bilateral intraputaminal infusion using a single infusion cannula in one

surgical session at two sites (anterior and posterior) per putamen. The infusion cannula is placedand infusion performed separately for each target point (see Figure 2).

- Tightly connect the syringe containing the prepared KEBILIDI to Luer Lock connector at the proximal end of the infusion cannula.
- 190 2. Load syringe onto the infusion pump and secure appropriately.
- 3. Set infusion pump occlusion limit to the highest level to prevent pump from alarming or disrupting the infusion.
- 4. Prime KEBILIDI at the rate of up to 0.003 mL/minute (0.18 mL/hour) until the first drop of the product can be seen at the tip of the needle.
- 195 5. Place sterile absorbent pad or gauze under the tip of the cannula to contain drops of the196 prepared product that might emerge during priming.
- 1976. Run the infusion pump prior to insertion of the cannula to ensure the prepared product is198flowing from the tip immediately before insertion.
- 1997. Place the infusion SmartFlow Neuro Cannula at the designation point in the putamen using stereotactic tools based on pre-planned stereotactic trajectories.
- 8. Starting with the first target site, insert the cannula through a burr hole into the putamen and then incrementally withdraw cannula along the intraputaminal infusion track, distributing the 0.08 mL (infused at a rate of 0.003 mL/min) of KEBILIDI per putamen across the planned trajectory to optimize distribution across the target site. The pump should run continuously throughout the 27-minute infusion, including during the repositioning to the designated sites along the infusion track.
- 9. Once the infusion is complete, stop the pump and leave the cannula in place for 5 minutes
 before withdrawing. Re-zero the total delivered volume setting on the infusion pump as
 soon as the cannula is inserted to the target and perform infusion. Reinsert at the next
 target point, repeating the same procedure for the other 3 target points.

- 211
- 10. After standard neurosurgical closure procedures, carry out a postoperative brain imaging
 examination of the patient to ensure there are no complications (e.g., bleeding).

214 **3 DOSAGE FORMS AND STRENGTHS**

- KEBILIDI is a sterile suspension for intraputaminal infusion. Each single-dose vial contains 216 2.8×10^{11} vg/0.5 mL (nominal concentration of 5.6×10^{11} vg/mL) of KEBILIDI and each 2 mL
- vial contains an extractable volume of 0.5 mL.
- Following product thaw, the suspension for infusion is a clear to slightly opaque, colorless to faint white liquid, free of visible particulates [see How Supplied/Storage and Handling (16)].

220 4 CONTRAINDICATIONS

221 KEBILIDI is contraindicated in patients who have not achieved skull maturity assessed by

neuroimaging. Skull maturity is needed for stereotactic neurosurgical administration ofKEBILIDI.

224 5 WARNINGS AND PRECAUTIONS

225 5.1 Procedural Complications

226 Procedural complications have been reported after neurosurgery required for KEBILIDI

administration. These events included respiratory and cardiac arrest which occurred within 24

hours of the neurosurgical procedure and during post-surgical care [see Adverse Reactions (6)].

229 KEBILIDI administration has the potential risk for additional procedure related adverse events

- 230 including cerebrospinal fluid (CSF) leak, intracranial bleeding, neuroinflammation, acute
- 231 infarction, and infection.
- Monitor patients for procedure related adverse events with KEBILIDI administration, includingcontinuous cardiorespiratory monitoring during hospitalization.

234 5.2 Dyskinesia

235 Dyskinesia was reported after administration of KEBILIDI. All events were reported within 3

- months of administration and 2 events required hospitalization [see Adverse Reactions (6)].
- 237 Monitor patients for signs and symptoms of dyskinesia after KEBILIDI treatment which may
- include involuntary movements of face, arm, leg, or entire body. These may present as fidgeting,
- writhing, wriggling, head bobbing or body swaying. The use of dopamine antagonists may be
- 240 considered to control dyskinesia symptoms.

2416ADVERSE REACTIONS

242 6.1 Clinical Trials Experience

243 Because clinical trials are conducted under widely varying conditions, adverse reaction rates

observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials

of another drug and may not reflect the rates observed in practice.

- 246 The safety data described in this section reflects exposure to KEBILIDI in 13 pediatric patients
- with genetically confirmed AADC deficiency who received a single dose of 1.8×10^{11} vg. The
- median duration of follow-up was 72 weeks (range 23 to 109 weeks) [see Clinical Studies (14)].
- The most common adverse reactions (incidence $\geq 15\%$) are summarized in Table 3.

250Table 3:Adverse Reactions in ≥15% of Patients in Study 1

Adverse Reaction	Patients Treated with KEBILIDI N=13 (%)
Dyskinesia	10 (77%)
Pyrexia	5 (38%)
Hypotension	4 (31%)
Anemia	4 (31%)
Salivary hypersecretion	3 (23%)
Hypokalemia	3 (23%)
Hypophosphatemia	3 (23%)
Insomnia	3 (23%)
Hypomagnesemia	2 (15%)
Procedural complications*	2 (15%)

251 *Procedural complications included respiratory and cardiac arrest.

252 Other clinically significant adverse reaction includes worsening in duration and frequency of

oculogyric crises during hospitalization following administration of KEBILIDI reported in one
 patient.

255 8 USE IN SPECIFIC POPULATIONS

256 8.1 Pregnancy

257 <u>Risk Summary</u>

There are no clinical data from the use of KEBILIDI in pregnant women. Animal reproductive and developmental toxicity studies have not been conducted with KEBILIDI.

- 260 In the US general population, the estimated background risk of major birth defects and
- miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

262 8.2 Lactation

263 <u>Risk Summary</u>

There is no data on the presence of KEBILIDI in human milk, the effects on the breastfed infant,or the effects on milk production.

266 8.3 Females and Males of Reproductive Potential

- 267 <u>Pregnancy Testing</u>
- 268 Pregnancy status of females with reproductive potential should be verified. Sexually active
- females of reproductive potential should have a negative pregnancy test before administeringKEBILIDI.

271 <u>Contraception</u>

- 272 There are insufficient exposure data to provide a recommendation concerning duration of
- contraception following treatment with KEBILIDI.
- 274 <u>Infertility</u>
- There is no data on the effects of KEBILIDI on fertility.

276 **8.4 Pediatric Use**

- 277 The safety and effectiveness of KEBILIDI have been established in pediatric patients. The use of
- KEBILIDI was evaluated in a single-arm, open-label study that enrolled 13 pediatric patients aged 16 months to 10 years who had achieved skull maturity *[see Adverse Reactions (6) and*
- aged 16 months to 10 years who had achieved skull maturity [see Adverse Reactions (6) and *Clinical Studies (14)*].
- The safety and effectiveness of KEBILIDI have not been studied in pediatric patients younger than 16 months.

283 8.5 Geriatric Use

KEBILIDI has not been studied in patients 65 years of age and older.

285 11 DESCRIPTION

- 286 KEBILIDI (eladocagene exuparvovec-tneq) is a gene therapy product that expresses the human
- aromatic L-amino acid decarboxylase enzyme (hAADC). It is a recombinant adeno-associated
- virus serotype 2 (rAAV2) based vector containing the complementary DNA of the human *DDC*
- 289 gene under the control of the cytomegalovirus immediate-early promoter. Eladocagene
- 290 exuparvovec-tneq is produced in human embryonic kidney cells by recombinant DNA
- technology.
- 292 KEBILIDI is a sterile suspension administered by bilateral intraputaminal infusion in one
- surgical session at two sites (anterior and posterior) per putamen. Each single-dose 2 mL vial
- contains 2.8×10^{11} vg in an extractable volume of 0.5 mL of suspension. Each mL of suspension
- 295 contains 5.6×10^{11} vg. Patients will receive a total dose of 1.8×10^{11} vg delivered as four 0.08 mL
- 296 $(0.45 \times 10^{11} \text{ vg})$ infusions (two per putamen).
- 297 KEBILIDI is provided in a single-dose 2 mL vial containing a clear to slightly opaque, colorless
- to faint white liquid, free of visible particulates following thaw from its frozen state. The
- excipients include potassium chloride (3 mM), sodium chloride (337 mM), potassium
- dihydrogen phosphate (2 mM), disodium hydrogen phosphate (8 mM), and poloxamer 188
 (0.001%).

302 12 CLINICAL PHARMACOLOGY

303 12.1 Mechanism of Action

- 304 KEBILIDI is a recombinant adeno-associated virus serotype 2 (rAAV2) based gene therapy
- designed to deliver a copy of the DDC gene which encodes the AADC enzyme. Intraputaminal
- 306 infusion of KEBILIDI results in AADC enzyme expression and subsequent production of
- 307 dopamine in the putamen.

308 12.2 Pharmacodynamics

309 <u>Homovanillic Acid in Cerebrospinal Fluid</u>

- 310 In Study 1, homovanillic acid (HVA), a downstream metabolite of dopamine, in cerebrospinal
- fluid (CSF) was measured at baseline, Week 8, and Week 48 using a high-performance liquid
- chromatography with tandem mass spectrometry (HPLC-MS/MS). In all patients of Study 1, an
- increase in CSF HVA levels from baseline was observed at Week 8 and Week 48 (Table 4).

314Table 4:HVA Levels in CSF (Study 1)

Timepoint	Observed Values (nmol/L)	Change from Baseline (nmol/L)	Percent Change from Baseline (%)
Baseline			
Ν	13	-	-
Median (Min, Max)	3.34 (1.00, 93.73)	-	-
Week 8			
Ν	12	12	12
Median (Min, Max)	35.09 (15.09, 150.48)	26.62 (12.49, 56.75)	534.7 (57.4, 2810.0)
Week 48			
Ν	9	9	9
Median (Min, Max)	29.16 (14.21, 125.84)	24.7 (13.21, 58.02)	773.1 (33.9, 3991.0)

315 Note: Lower limit of quantification (LLOQ) was 2 nmol/L, and values reported as <LLOQ were imputed as 0.5*LLOQ.

316 Abbreviations: CSF=cerebrospinal fluid; HVA=homovanillic acid; N=number of subjects; Max=maximum;

317 Min=minimum

318 ¹⁸F-DOPA Uptake in the Putamen

¹⁸F-DOPA is a positron-emitting fluorine-labeled substrate of the AADC enzyme. Following

administration of 18 F-DOPA, its uptake into the putamen assessed by positron emission

tomography (PET) imaging reflects AADC enzyme activity of dopaminergic neurons in the

322 putamen. In Study 1, ¹⁸F-DOPA uptake in the putamen was assessed at baseline and followed up

at Week 8 in 12 out 13 patients and at Week 48 in 10 out 13 patients indicating increased AADC

¹⁸F-DOPA uptake in all assessed patients. The median (range) percent increase from baseline

was 259% (65% to 620%) at Week 8 and 271% (25% to 760%) at Week 48.

326 12.3 Pharmacokinetics

- 327 <u>Biodistribution (within the body) and Vector Shedding (excretion/secretion)</u>
- 328 KEBILIDI vector DNA levels in various tissues and secretions were determined using a
- validated quantitative polymerase chain reaction (qPCR) assay.

330 Nonclinical data

- Biodistribution of eladocagene exuparvovec-tneq was evaluated in rats at Days 7, 30, 90, and
- 180 after single-dose intraputational infusion at dose levels up to 7.5×10^9 vg/animal (21-fold
- higher than the recommended human dose based on relative brain weight). At Day 7, vector
- DNA was observed in the putamen, cerebellum, cerebrum, and spinal cord. Vector DNA levels
- declined from Day 7 to Day 90, with DNA levels primarily sustained in the putamen at Day 180.

336 *Clinical data*

- Following administration of KEBILIDI at a total dose for each patient of 1.8×10^{11} vg in Study 1,
- biodistribution and viral shedding in CSF, blood, and urine were evaluated in 13 patients. CSF
- was collected at Weeks 8 and 48, and blood and urine were collected from Day 3 up to Week 48.
- Five (38%) patients showed detectable vector DNA levels in blood at Day 3 ranging from
- 341 4.0×10^3 to 6.5×10^3 copies/mL, which became below the limit of detection (<3.1×10³ copies/mL)
- by Week 3. No vector was detected in CSF or urine.

343 12.6 Immunogenicity

- The observed incidence of anti-AAV2 antibodies is highly dependent on the sensitivity and
- specificity of the assay. Differences in assay methods preclude meaningful comparisons of the
- incidence of anti-AAV2 antibodies in the studies described below with the incidence of anti-
- 347 AAV2 antibodies in other studies.
- There is no clinical experience with KEBILIDI in patients with pre-existing anti-AAV2
 neutralizing antibody at titers >1:1200.
- 350 In Study 1, anti-AAV2 total binding antibodies and anti-AAV2 neutralizing antibodies were
- assessed from Day 3 up to Week 48 following administration of KEBILIDI. In all patients
- 352 (N=13), titers of total binding antibody and neutralizing antibody increased from Week 3 and
- remained elevated, as measured at Week 48 (N=9). The highest titers in each patient ranged from
- 1:800 to 1:204,800 for total binding antibodies and from 1:80 to 1:10,240 for neutralizing
- antibody. Because of the small sample size of Study 1, there is insufficient data to determine the
- 356 effect of anti-AAV2 antibody on the pharmacokinetics, pharmacodynamics, safety, or
- 357 effectiveness.

358 13. NONCLINICAL TOXICOLOGY

359 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, genotoxicity, and fertility studies have not been performed with KEBILIDI.

361 14 CLINICAL STUDIES

The efficacy of KEBILIDI was evaluated in one open-label, single arm study (Study 1;

- 363 NCT04903288). The study enrolled pediatric patients with genetically confirmed, severe AADC
- deficiency who had achieved skull maturity assessed with neuroimaging. The main efficacy
- outcome measure was gross motor milestone achievement evaluated at week 48 and assessed
- using the Peabody Developmental Motor Scale, Second Edition (PDMS-2). Patients treated with KEPH IDI were compared to an automal waterest ad natural history school of 42 and intrinst
- 367 KEBILIDI were compared to an external untreated natural history cohort of 43 pediatric patients
 368 with severe AADC deficiency who had at least one motor milestone assessment after 2 years of
- 369 age.
- A total of 13 patients received a single total dose of 1.8×10^{11} vg of KEBILIDI given as four
- intraputaminal infusions in a single stereotactic neurosurgical procedure. The demographic
- characteristics of the population were as follows: the median age was 2.8 years (1.3 to 10.8
- years), 7 patients (54%) were female, 10 patients (77%) were Asian, 2 patients (15%) were
- White, and 1 patient was of "other" race. Twelve of the 13 patients had the severe phenotype of
- AADC deficiency, defined as having no motor milestone achievement at baseline and no clinical
- response to standard of care therapies. The one remaining patient had a "variant" of the severe
- disease phenotype, with the ability to sit with assistance but with lack of head control.
- Gross motor milestone achievement at Week 48 was assessed in 12 of the 13 patients treated inStudy 1 (one patient dropped out of the study prior to Week 48).
- Eight (67%) of the 12 treated patients achieved a new gross motor milestone at week 48: 3
- patients achieved full head control, 2 patients achieved sitting with or without assistance, 2
- patients achieved walking backwards and the patient with the "variant" severe phenotype was
- able to sit unassisted. The two patients who achieved walking backwards at week 48 were treated
 before 2 years of age. The four patients who were unable to achieve new gross motor milestones
- at week 48 were treated between the ages of 2.8 and 10.8 years. In comparison, none of the 43
- untreated patients with the severe phenotype had documented motor milestone achievement at
- last assessment at a median age of 7.2 years (range 2 to 19 years).

388 16 HOW SUPPLIED/STORAGE AND HANDLING

389 <u>How Supplied</u>

- KEBILIDI is supplied in a single-dose 2 mL vial containing sterile, clear to slightly opaque,
- colorless to faint white liquid free of visible particulates, following thaw from its frozen state.
- Each KEBILIDI (eladocagene exuparvovec-tneq) vial contains 2.8×10^{11} vg of eladocagene
- exuparvovec-tneq in an extractable volume of 0.5 mL of suspension. Each mL of suspension
- 394 contains a nominal concentration of 5.6×10^{11} vg of eladocagene exuparvovec-tneq.
- 395 Package (carton): NDC Number 52856-601-01
- Container (vial): NDC Number 52856-601-11

- 397 <u>Storage and Handling</u>
- 398 Store and transport frozen at \leq -65°C (-85°F). Keep the vial in the supplied carton.

399 Thaw KEBILIDI prior to administration. If not used immediately, store at room temperature (up

400 to 25°C [77°F]) and use within 6 hours of starting product thaw [see Dosage and Administration

401 (2.3)]. **Do not** refreeze vial once thawed.

402 17 PATIENT COUNSELING INFORMATION

- 403 Discuss the following with patients and caregivers:
- Administration: Inform patients/caregivers that KEBILIDI administration involves an infusion into the brain that is administered during the neurosurgical procedure [see Administration 2.4)].
- Procedural Complications: Inform patients/caregivers about the complications of the neurosurgical procedure required for administration of KEBILIDI, including respiratory and cardiac arrest, cerebrospinal fluid (CSF) leak, intracranial bleeding, neuroinflammation, acute infarction, and infection *[see Warnings and Precautions (5.1)]*.
- Dyskinesia: Inform patients/caregivers that they may experience dyskinesia within 3 months after treatment with KEBILIDI. Symptoms of dyskinesia may include involuntary movements of face, arm, leg, or entire body which may present as fidgeting, writhing, wriggling, head bobbing or body swaying. Advise patients and caregivers to contact their healthcare provider if these symptoms occur [see Warnings and Precautions (5.2)].
- Vector Shedding: Inform patients/caregivers that temporary vector shedding of KEBILIDI may occur for 3 weeks after administration. Advise patients/caregivers on proper hand hygiene and appropriate handling of waste materials generated from dressings and/or any secretions (e.g., blood, nasal secretions, urine, stool, and CSF).
 Recommended procedures include storage of waste material in sealed bags prior to disposal and wearing gloves for dressings changes and waste disposal. Patients should
- 423 not donate blood, organs, tissues, or cells for transplantation [see *Pharmacokinetics*424 (12.3)].
- 425
- 426 Manufactured by: PTC Therapeutics, Inc.
- 427 Warren, NJ 07059 USA
- 428
- 429 US License No. 2168